Scherdel P, Dunkel L, van Dommelen P, Goulet O, Salaün JF, Brauner R, Heude B, Chalumeau M (14 de enero de 2016). «Growth monitoring as an early detection tool: a systematic review». Lancet Diabetes Endocrinol (Revisión). pii: S2213-8587 (15): 00392-7. PMID26777129. doi:10.1016/S2213-8587(15)00392-7. «Conclusion. At present, growth-monitoring practices in most countries are based on insufficient data and suboptimal methods, resulting in delayed diagnosis of severe disorders, inappropriate referrals of disease-free children with normal variants of growth, and high health-care
costs. Although incompletely validated, three algorithms seem the most promising —the Grote and Saari clinical decision rules25,29,31— but clinicians should keep in mind that an algorithm is a decision-making companion that will never replace their own clinical assessment and judgment. Further investigations are needed to standardise the practice of growth monitoring, with a
consensus on a few priority target conditions and with internationally validated clinical decision rules to define abnormal growth, including the selection of appropriate growth charts. The shift from experience-based to evidence-based growth monitoring will be possible only with the effort of primary-care health professionals to routinely and correctly measure children’s height and weight, and plot the measurements on growth charts.»
Scherdel P, Dunkel L, van Dommelen P, Goulet O, Salaün JF, Brauner R, Heude B, Chalumeau M (14 de enero de 2016). «Growth monitoring as an early detection tool: a systematic review». Lancet Diabetes Endocrinol (Revisión). pii: S2213-8587 (15): 00392-7. PMID26777129. doi:10.1016/S2213-8587(15)00392-7. «Conclusion. At present, growth-monitoring practices in most countries are based on insufficient data and suboptimal methods, resulting in delayed diagnosis of severe disorders, inappropriate referrals of disease-free children with normal variants of growth, and high health-care
costs. Although incompletely validated, three algorithms seem the most promising —the Grote and Saari clinical decision rules25,29,31— but clinicians should keep in mind that an algorithm is a decision-making companion that will never replace their own clinical assessment and judgment. Further investigations are needed to standardise the practice of growth monitoring, with a
consensus on a few priority target conditions and with internationally validated clinical decision rules to define abnormal growth, including the selection of appropriate growth charts. The shift from experience-based to evidence-based growth monitoring will be possible only with the effort of primary-care health professionals to routinely and correctly measure children’s height and weight, and plot the measurements on growth charts.»
